GS-441524 (NeoFipronis) Indications and Dosage
Feline Infectious Peritonitis (FIP) is a serious, often fatal disease caused by a mutated feline coronavirus. It affects cats worldwide, presenting with symptoms such as anorexia, lethargy, fever, ascites, pleural effusion, lymphadenopathy, granulomatous inflammation, neurological deficits, and uveitis. Traditionally, FIP has been challenging to treat, but recent advancements have introduced effective antiviral therapies like GS-441524, marketed as NeoFipronis (Pronidesivir).
NeoFipronis (Pronidesivir) is the world's first approved oral medication specifically designed to combat FIP. Approved by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026, it has obtained official drug registration, marking a milestone in veterinary medicine. This medication offers a safe, non-invasive, rapidly absorbed, and well-tolerated treatment option with minimal side effects. The active component, GS-441524, has undergone extensive research and clinical trials, demonstrating potent antiviral activity against feline coronavirus mutations responsible for FIP.
The mechanism of action involves inhibiting viral RNA synthesis, effectively controlling viral proliferation. NeoFipronis’s unique formulation ensures quick absorption, leading to rapid symptom alleviation. The treatment regimen is designed for ease of use and efficacy, emphasizing the importance of adherence to dosage instructions for optimal outcomes.
Indications
NeoFipronis is indicated for cats diagnosed with FIP exhibiting clinical symptoms such as inappetence, depression, fever, abdominal or thoracic effusion, lymph node enlargement, granulomas, neurological damage, or ocular inflammation. It is especially effective in managing both wet (effusive) and dry (non-effusive) forms of FIP.
Dosage and Administration
The recommended dosage depends on the cat’s weight:
For most cases: 15 mg per kilogram of body weight daily (equivalent to half a tablet).
For neurological or ocular FIP manifestations: the dose may be increased to 30 mg/kg daily, as per veterinary guidance.
Administration should be consistent, with medication given once daily, preferably on an empty stomach—either one hour before feeding or two hours after meals—to maximize absorption. Treatment duration generally lasts no less than 12 weeks to ensure viral clearance and symptom resolution. Compliance is vital; missed doses can reduce treatment efficacy and risk relapse.
Monitoring and Precautions
During therapy, cat owners should closely monitor for changes in appetite, body temperature, energy levels, and overall well-being. Periodic blood tests assessing liver and kidney functions are recommended to identify any adverse reactions early. Although NeoFipronis is classified as an over-the-counter medication, veterinary supervision is strongly advised to tailor dosage, monitor progress, and address potential side effects.
Safety and Usage Guidelines
NeoFipronis (Pronidesivir) should be used exclusively in cats. Human consumption is strictly contraindicated. Buyers should verify authenticity and purchase only through official NeoFipronis websites or authorized veterinary outlets to ensure product quality and safety. Proper storage in a cool, dry place is recommended to maintain drug integrity.
Conclusion
NeoFipronis represents a breakthrough in FIP treatment, providing a safe, effective, and easy-to-administer antiviral therapy that revolutionizes feline health management. Its approval marks a significant step forward in combating this once-devastating disease, offering hope for cats worldwide suffering from FIP. Veterinary consultation remains essential to ensure proper use, optimize outcomes, and safeguard animal health.
For more information, visit NeoFipronis official website or consult your veterinarian to determine if this innovative therapy is suitable for your cat.
